Skip to Content

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

Professor Eric Pujade-Lauraine and his team have investigated if patients suffering from ovarian carcinoma who relapse after first line treatment with Olaparib (PARP inhibitor) will benefit of maintenance restarting of the same drug. Results suggest significant improvement in progression free survival, regardless of BRCAm or HRD status.

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top